Warning letter
Hubei Gedian Humanwell Pharmaceutical Co., Ltd.: warning letter of Jun 3, 2026
FDA warning letter 725591 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 725591 |
|---|---|
| Company | Hubei Gedian Humanwell Pharmaceutical Co., Ltd. |
| Subject | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated |
| Issue date | Jun 3, 2026 |
| Posted date | Jun 9, 2026 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| Inspection city | Ezhou |
| Inspection start date | Nov 3, 2025 |
| Letter on fda.gov | fda.gov |
At a glance
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: